Yufeng Huang
VerifiedColumbia University · American Language Program
Active 2005–2024
Research topics
- Intensive care medicine
- Internal medicine
- Oncology
- Medicine
Selected publications
Breakthrough in targeted therapy for non-small cell lung cancer
Biomedicine & Pharmacotherapy · 2020 · 103 citations
- Medicine
- Oncology
- Internal medicine
Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.
Frequent coauthors
- 743 shared
Jason D. Wright
- 558 shared
Dawn L. Hershman
Columbia University Irving Medical Center
- 526 shared
June Y. Hou
NewYork–Presbyterian Hospital
- 429 shared
Ana I. Tergas
- 344 shared
Cande V. Ananth
Rutgers, The State University of New Jersey
- 340 shared
Fady Khoury‐Collado
- 337 shared
Caryn M. St. Clair
Herbert Irving Comprehensive Cancer Center
- 333 shared
Alfred I. Neugut
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Yufeng Huang
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup